Actinidia eriantha Polysaccharide and PD1-Antibody Combination Therapy | OTT – Dove Medical Press

Jinxia Li,1 Yiping Wang,2 Weiyang Jin,3 Li Shen4

1College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, 410208, Peoples Republic of China; 2Key Laboratory of Digestive Pathophysiology of Zhejiang Province, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310006, Peoples Republic of China; 3School of Life and Environmental Science, Hangzhou Normal University, Hangzhou, 311121, Peoples Republic of China; 4Institute of Basic Theory of TCM, China Academy of Chinese Medical Sciences, Beijing, 100700, Peoples Republic of China

Correspondence: Li ShenInstitute of Basic Theory of TCM, China Academy of Chinese Medical Sciences, Beijing, 100700, Peoples Republic of ChinaTel +86-158-5825-6870Email shenli1116@126.com

Objective: To observe the efficacy of Actinidia eriantha polysaccharide (AEPS) combined with PD1 antibody therapy in colorectal cancerxenograft mice.Methods: CT26 cells were inoculated into 80 C57BL/6 mice to establish the colorectal cancer xenograftmouse model. Mice were divided evenly into a model group, AEPS group, anti-PD1 group, and combined group. AEPS 5mL/kgday was given orally and 10 mg/kg anti-PD1 injected intravenously for 28 days. Tumor growth and mouse survival were observed. Tumor-cell proliferation and metastasis markers Ki67, N-cadherin, KLF4, and Oct4 were detected with immunochemistry and Western blotting, T-cell infiltration in spleens and tumors was detected with MTT and flow cytometry. IFN and TNF were detected with ELISA.Results: Tumor growth was significantly retarded and survival prolonged in the AEPS, anti-PD1, and combined groups. Ki67 expression decreased in the anti-PD1 and combined groups, and N-cadherin, KLF4, and Oct4 expression decreased in the AEPS and combined groups. IFN and TNF levels, T-cell infiltration in spleen, and tumor all increased distinctively in the AEPS and combined groups. The combined group showed better antitumor effects and life-extension effect than the other two groups.Conclusion: AEPS and PD1 antibody-combination therapy can suppresses tumor growth and prolong survival of colorectal cancerxenograft mice by regulating immunofunction, and the combined therapy showed better therapeutic efficacy than the single treatment.

Keywords: colorectal cancer, PD1 antibody, Actinidia eriantha polysaccharide, combined therapy

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read more here:

Actinidia eriantha Polysaccharide and PD1-Antibody Combination Therapy | OTT - Dove Medical Press